Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2009-03-31
2011-10-04
Yu, Misook (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S183000
Reexamination Certificate
active
08029799
ABSTRACT:
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
REFERENCES:
patent: 5861406 (1999-01-01), Wehrmann
patent: 5888980 (1999-03-01), Ripka
patent: 6462017 (2002-10-01), Rudolph et al.
patent: 7101598 (2006-09-01), Hubbard
patent: 7297676 (2007-11-01), Rudolph et al.
patent: 2003/0185799 (2003-10-01), Rudolph
patent: 2004/0235829 (2004-11-01), Scott et al.
patent: 2005/0049191 (2005-03-01), Rudolph et al.
patent: 2008/0300166 (2008-12-01), Tuthill et al.
patent: 2010/0016211 (2010-01-01), Tuthill et al.
patent: 2010/0197595 (2010-08-01), Tuthill et al.
patent: 2002363248 (2003-05-01), None
patent: 10509955 (1998-09-01), None
patent: 9615800 (1996-05-01), None
patent: 0182949 (2001-11-01), None
SciClone Press release (Dec. 2005, http://findarticles.com/p/articles/mi—pwwi/is—200512/ai—n15918545/print?tag=artBody;col1, pp. 1-3).
Walsh (Nov. 2006, http://www.articlearchives.com/pharmaceuticals-biotechnology/pharmaceuticals/802926-1.html, pp. 1-2).
Balch et al (J. Clin. Onc., 19(16):3635-3648, 2001.
Lopez et al (Annals of Onc., 5:741-746, 1994).
Ancell et al (Am J Health-Syst Pharm, 58:879-888, 2001).
Eton et al (J. Clin. Onc., 20(8):2045-2052, 2002).
Rasi et al (Mel. Res. 10:189-192, 2000).
Pica et al (Anticancer Res., 18:3571-3578, 1998).
Chadwick et al Clin. Exp. Immun. 134:477-481, 2003).
Atallah et al (Curr. Treat. Opt. Onc., 6:185-193, May 2005).
Billich (Curr. Opin. Inv. Drugs, 3(5):698-707, 2002).
Avril, M.F., et al., Fotemustine Compared With DaCarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study, J. of Clinical Oncology, Mar. 15, 2004, pp. 1118-1125, vol. 22, No. 6.
Deichmann, Martin, et al., S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV Melanoma, J. of Clinical Oncology, Jun. 1999, pp. 1891-1896, vol. 17, No. 6.
Eton, Omar, et al., Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Radomized Trial, J. of Clinical Oncology, Apr. 2002 pp. 2045-2052, vol. 20, No. 8.
Fink, M., et al, A phase II trial of DTIC with thalidomide (thal) in metastatic melanoma (MM), J. of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004, pp. 7543, vol. 22, No. 14S (Jul. 15 Supplement).
Garaci, Enrico, et al., Thymosin Alpha 1, From Bench to Bedside, Annals of the N.Y. Academy of Science, 2007, pp. 225-234, vol. 1112.
Garaci, Enrico, et al., Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application, Int'l J. of Immunopharmacology, 2000, pp. 1067-1076, vol. 22.
Ishitsuka, H., et al., Protective activity of thymosin α1 against tumor progression in immunosuppressed mice, Adv. Exp. Med Biol, 1983, pp. 89-100, vol. 166.
Mackiewicz, A., et al., A first-line, phase II study with dacarbazine (DTIC) plus thymosin alpha 1 (Ta1) with or without interferon alpha (IFNa) vs. DTIC plus IFNa in stage IV melanoma, Abstracts of the Perspectives in Melanoma X and The Third Annual International Melanoma Research Congress, Sep. 2006, pp. S39, vol. 16.
Millward, M. J., et al., Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM); Analysis of long-term survival, J. of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004, pp. 7505, vol. 22, No. 14S (Jul. 15 Supplement).
Schadendorf, D., et al., Dacarbacine (DTIC) versus vaccination with autologus peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III study, J. of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004, pp. 7508, vol. 22, No. 14S (Jul. 15 Supplement).
Therasse, Patrick, et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, J. Nat'l Cancer Inst, 2000, pp. 205-216, vol. 92, No. 3.
Third International Symposium on Combination Therapies, Institute for Advanced Studies of Immunology & Aging, Houston, TX, Oct. 29 thru 31, 1993, 2 pages.
U.S. Appl. No. 11/858,640, Non-Final Office Action mailed Apr. 15, 2009.
U.S. Appl. No. 11/858,640, Final Office Action mailed Oct. 27, 2009.
U.S. Appl. No. 11/424,475, Non-Final Office Action mailed Dec. 12, 2007.
U.S. Appl. No. 11/424,475, Final Office Action mailed May 14, 2008.
U.S. Appl. No. 11/424,475, Non-Final Office Action mailed Jan. 23, 2009.
U.S. Appl. No. 11/734,592, Non-Final Office Action mailed Dec. 13, 2007.
U.S. Appl. No. 11/734,592, Final Office Action mailed Oct. 29, 2008.
U.S. Appl. No. 11/734,592, Non-Final Office Action mailed May 19, 2009.
U.S. Appl. No. 11/734,592, Final Office Action mailed Nov. 25, 2009.
NZ Application No. 574170 Examination Report dated Jun. 4, 2010.
International Search Report with International Publication No. WO2007/144218 A1, Int'l Publication Date Dec. 21, 2007.
International Preliminary Report on Patentability for International Application No. PCT/EP2007/053712, issued Dec. 16, 2008.
IL Application No. 195955 Office Action, mailed Mar. 3, 2011.
Non-Final Office Action mailed on Aug. 2, 2010 in related U.S. Appl. No. 11/734,592.
Camerini Roberto
Carminati Paolo
Martins Eduardo R.
Rudolph Alfred R.
Singrossi, legal representative Maria Gabriella
Cooley LLP
Duffy Brad
SciClone Pharmaceuticals Inc.
Yu Misook
LandOfFree
Use of thymosin alpha 1 for preparing a medicament for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of thymosin alpha 1 for preparing a medicament for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of thymosin alpha 1 for preparing a medicament for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285732